Newsletter Subject

This Nasdaq Profile (Inside) Is On Immediate Alert (4 Intriguing Potential Catalysts)

From

fierceanalyst.net

Email Address

jaks@fierceanalyst.ccsend.com

Sent On

Mon, Aug 5, 2024 01:00 PM

Email Preheader Text

Friday we saw a breakout runner make a major move. This Nasdaq Profile Is On Immediate Alert ? Aug

Friday we saw a breakout runner make a major move. This Nasdaq Profile (CTXR) Is On Immediate Alert (4 Intriguing Potential Catalysts)  August 5th Dear Reader, Timing could be critical to get this Nasdaq Biopharma on your radar right now: *Citius Pharmaceuticals, Inc. (Nasdaq: CTXR)* Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. And based on several potential catalysts, CTXR could earn some serious breakout buzz near term. Check them out: No. 1 CTXR Potential Catalyst - August 13th FDA Decision Could Lead To Product Commercialization! Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates CRANFORD, N.J., July 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), ..., today announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date. Leonard Mazur, Chairman and CEO of Citius stated, "Our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months. Mino-Lok's strong Phase 3 topline results support its potential to become part of the standard of care for treating catheter-related bloodstream infections. Mino-Lok would also have a first and only advantage in a market with no approved or investigational products for salvaging infected central venous catheters. For LYMPHIR™, the FDA is currently reviewing our Biologics License Application, with an expected decision on August 13th. We are preparing for near-term commercialization of LYMPHIR if approved. These near-term catalysts should enable the company to optimize its current cash runway, future cash needs, as well as create potential non-dilutive cash opp's." ... [Read the full article here.]( ----- No. 2 CTXR Potential Catalyst - Positive Topline Results In Phase 3 Clinical Trial Makes CTXR A Biotech To Take Seriously. Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution CRANFORD, N.J., May 21, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), ..., today announced positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok®, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI). The study met its primary endpoint with a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to Control arm patients receiving clinician-directed anti-infective lock solution. The data demonstrate that Mino-Lok is well-tolerated. ... [Read the full article here.]( ----- No. 3 CTXR Potential Catalyst - Analysts Combined Targets Suggest Must-See Upside Potential From Current Levels! Take a look at what's being reported over at [TipRanks]( The graphic above shows that 3 different Wall Street analysts believe CTXR could be undervalued from current levels. In fact, with their combined targets, there may be over 400% potential upside for CTXR from current levels. Just imagine how important this August 13th FDA decision could be... ----- No. 4 CTXR Potential Catalyst - Closing Above 3 Key Technical Lines Means Chart Support Could Be Strengthening. Take a peek at CTXR's 3-month chart: On Friday, CTXR closed above 3 important technical chart lines in its: - 50-Day Simple Moving Average (SMA), its - 200-Day SMA, and its - 13-Day Exponential Moving Average (EMA). If support at those levels strengthens and CTXR is able to take on and break down $1.00 psychological resistance, big things could lie ahead for this Nasdaq Biopharma. ----- CTXR Recap - Key Catalyst Potential Could Create A Breakout Spark Near Term No. 1 - August 13th FDA Decision Could Lead To Product Commercialization! No. 2 - Positive Topline Results In Phase 3 Clinical Trial Makes CTXR A Biopharma To Take Seriously. No. 3 - Analysts Combined Targets Suggest Must-See Upside Potential From Current Levels! No. 4 - Closing Above 3 Key Technical Lines Means Chart Support Could Be Strengthening. ----- Coverage is officially initiated on (Nasdaq: CTXR). Get this Biotech profile front and center this week. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media, LLC, FierceInvestor (FI) has been hired for a period beginning on 8/4/24 and ending on 8/5/24 to publicly disseminate information about (CTXR) via Website, Email and SMS. SWN Media LLC was paid fifteen thousand USD via bank wire transfer. We own zero shares of (CTXR). In the last [93] days we have been paid a total of fifteen thousand USD. We own zero shares of (CTXR:US). SWN Media LLC has long standing paid publicity agreements for (CTXR:US). Please contact us for more information about amounts paid for publicly disseminating information in previous periods. A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 08/04/2024 and ending on 08/05/2024 to publicly disseminate information about (CTXR:US) via digital communications. We have been paid an additional forty thousand USD. We own zero shares of (CTXR:US). In the last [93] days we have been paid a total of two hundred seventy-four thousand five hundred USD. We own zero shares of (CTXR:US). TD Media LLC has long standing paid publicity agreements for (CTXR:US). Please contact us for more information about amounts paid for publicly disseminating information in previous periods. [( Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US [Unsubscribe]( | [Update Profile]( | [Constant Contact Data Notice](

Marketing emails from fierceanalyst.net

View More
Sent On

05/12/2024

Sent On

04/12/2024

Sent On

04/12/2024

Sent On

26/11/2024

Sent On

26/11/2024

Sent On

26/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.